Fort Collins, Colorado (PRWEB) October 21, 2013
KromaTiD, Inc. is pleased to announce the launch of its directional Genomic Hybridization™ (dGH™) line of mutation discovery and detection assays. Available immediately, KromaTiD dGH products provide researchers with unique tools for discovering new disease-causing mutations as well as studying the genetic roots of diseases such as cancers and developmental disorders.
Based on a proprietary chromatid-specific imaging platform, dGH products are the only imaging assays capable of determining DNA sequence, location and orientation data in a single test. With these three dimensions of high-resolution data, dGH assays can detect a wide range of disease-causing genetic rearrangements, including inversions and translocations.
According to Dr. Joel Bedford, chairman of the KromaTiD Scientific Advisory Board, the importance of cryptic DNA rearrangements (such as inversions) has not been fully appreciated until recently. “Mutations such as deletions and chromosomal rearrangements cause genetic diseases, including cancers and autism, by disrupting vital biological processes. Up until the launch of KromaTiD’s dGH products, however, most inversions - especially small ones - have been invisible to researchers. Now, with the ability of dGH to complement highly sophisticated sequencing approaches, we can begin to understand the full scope and impact of these DNA rearrangements on human disease,” explained Bedford.
The KromaTiD dGH product line includes a genome-wide set of tools for discovering disease-causing mutations, specific high-resolution tests for detecting diseases such as thyroid cancer, and an affordable custom assay service. Christopher Tompkins, President and COO of KromaTiD, says the company is committed to making these assays widely available and affordable. “We have been test-marketing our dGH kits for several months, and have been delighted with the res
Copyright©2012 Vocus, Inc.
All rights reserved